Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evofosfamide + Gemcitabine in Pancreatic Cancer
NCT01746979Phase 3Completed
- Sponsor
- ImmunoGenesis
- Start
- Dec 2012
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of evofosfamide in pancreatic ductal adenocarcinoma (PDAC), sponsored by ImmunoGenesis. Started Dec 2012; status: completed.
02
Drugs
evofosfamide
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01746979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01746979.